When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report

Unleashing adaptive immunity via immune checkpoint inhibitors (ICPIs) in many cancer types led to durable antitumor responses and prolonged survivals and also added some new immune-related adverse events (irAEs) to the ‘old-fashioned’ safety profile of chemotherapy. Among bowel and endocrine irAEs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziogas, Dimitrios C, Gkoufa, Aikaterini, Cholongitas, Evangelos, Diamantopoulos, Panagiotis, Anastasopoulou, Amalia, Ascierto, Paolo Antonio, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607607/
https://www.ncbi.nlm.nih.gov/pubmed/33144335
http://dx.doi.org/10.1136/jitc-2020-001322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607607/
https://www.ncbi.nlm.nih.gov/pubmed/33144335
http://dx.doi.org/10.1136/jitc-2020-001322

Ejemplares similares